



Prostate Cancer Biomarkers and Therapeutics

Guest Editor:

Dr. Kamlesh Kumar Yadav

School of Engineering Medicine,
Texas A&M University, Houston,
TX 77030, USA

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editor

Prostate cancer is one of the most common cancers in men worldwide. Since early detection is key to increased survival, significant developments have occurred recently with the advent of biomarkers such as PSA, PCA3, TMPRSS2-ERG fusion, etc. However, many of the screening biomarkers suffer from poor specificity and sensitivity and do not accurately predict survival or treatment outcomes. Thus, the development of new biomarkers and/or strategies for the incorporation of existing biomarkers with machine learning technology is urgently needed for accurate personalized diagnosis and treatment outcome predictions. On the treatment front, there has been an increase in the availability of new therapies, including targeted, combinatorial and immunotherapies. Although the mainstay of the therapy is targeting the androgen signaling axis, new strategies have recently been developed that are improving radiation and chemotherapy outcomes through the utilization of immune-targeted radiation therapy and personalized combinatorial chemo and immunotherapy. This Special Issue aims to consolidate recent advancements in prostate cancer biomarkers and therapeutics.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
X@Biomol_MDPI